Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Longitudinal, Non-randomized Study to Evaluate the Utility of the INanoBio's Protein Arrays in Detecting Unique Antibodies in COVID-19 Patients

NCT04465981 is registered in ClinicalTrials.gov with INanoBio Inc. as lead sponsor.

NCT NCT04465981
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04465981 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Longitudinal, Non-randomized Study to Evaluate the Utility of the INanoBio's Protein Arrays in Detecting Unique Antibodies in COVID-19 Patients
Lead sponsor
INanoBio Inc.
Phase
Observational
Overall status
Unknown status
Start date
July 3, 2020
Completion date
December 31, 2022
Enrollment
80 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19, sars-cov-2 infection